Recombinetics Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
26
- Latest Deal Type
-
Debt - PPP
- Latest Deal Amount
-
$766K
- Investors
-
11
Recombinetics General Information
Description
Developer of gene editing technologies designed to improve human health through advanced disease models and regenerative medicine. The company's technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools, enabling biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.
Contact Information
Website
www.recombinetics.comCorporate Office
- 3388 Collins Drive
- Eagan, MN 55121
- United States
Corporate Office
- 3388 Collins Drive
- Eagan, MN 55121
- United States
Recombinetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Debt - PPP | 14-Apr-2020 | $766K | Completed | Generating Revenue | ||
| 17. Later Stage VC | Completed | Generating Revenue | ||||
| 16. Grant | Completed | Generating Revenue | ||||
| 15. Grant | 01-Jan-2019 | Completed | Generating Revenue | |||
| 14. Later Stage VC (Series A) | 18-Sep-2018 | Completed | Generating Revenue | |||
| 13. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 12. Grant | 01-Jan-2017 | Completed | Generating Revenue | |||
| 11. Grant | 01-Jan-2017 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 14-Nov-2016 | $11M | $14.9M | Completed | Generating Revenue | |
| 9. Grant | 01-Jan-2016 | $1.46M | $3.88M | Completed | Generating Revenue |
Recombinetics Comparisons
Industry
Financing
Details
Recombinetics Competitors (35)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ProFactor Pharma | Venture Capital-Backed | Roslin, United Kingdom | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Voyager Therapeutics | Corporation | Cambridge, MA | ||||
| Qrons | Corporation | New York, NY | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Recombinetics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Recombinetics Patents
Recombinetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2022526836-A | Sterile fish | Pending | 09-Apr-2019 | ||
| US-20220015341-A1 | Sterile fish | Pending | 09-Apr-2019 | ||
| US-20210251200-A1 | Production method for animal models with disease associated phenotypes | Inactive | 31-Aug-2018 | ||
| US-20190183100-A1 | Animal models for polycystic kidney disease | Inactive | 19-Dec-2017 | ||
| US-20190045761-A1 | Inducible disease models methods of making them and use in tissue complementation | Inactive | 11-Aug-2017 | A01K67/0278 |
Recombinetics Executive Team (26)
| Name | Title | Board Seat |
|---|---|---|
| Rocco Morelli | Chief Executive Officer | |
| Sabreena Larson | Chief Operations Officer | |
| Dan Carlson Ph.D | Co-Chief Scientific Officer & Senior Vice President of Research & Development | |
| William Haupt | Director of Finance | |
| Douglas Keeth | Executive |
Recombinetics Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Corey Zarecki | Edge (Onalaska) | Board Member | |
| David Largaespada Ph.D | Self | Board Member | |
| Jerry Arndt | Self | Board Member | |
| Marylinn Munson | Self | Board Member | |
| Peter Hajas | Self | Chairman |
Recombinetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Recombinetics Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Cancer Institute | Government | |||
| National Institute of Dental and Craniofacial Research | Government | |||
| Edge (Onalaska) | Corporate Venture Capital | Minority | ||
| National institutes of Neurological Disorders and Stroke | Government | |||
| The National Institute on Aging (NIA) | Government |
Recombinetics FAQs
-
When was Recombinetics founded?
Recombinetics was founded in 2008.
-
Who is the founder of Recombinetics?
Scott Fahrenkrug Ph.D, Perry Hackett Ph.D, Dan Voytas Ph.D, and Joe Tector Ph.D are the founders of Recombinetics.
-
Who is the CEO of Recombinetics?
Rocco Morelli is the CEO of Recombinetics.
-
Where is Recombinetics headquartered?
Recombinetics is headquartered in Eagan, MN.
-
What is the size of Recombinetics?
Recombinetics has 26 total employees.
-
What industry is Recombinetics in?
Recombinetics’s primary industry is Biotechnology.
-
Is Recombinetics a private or public company?
Recombinetics is a Private company.
-
What is Recombinetics’s current revenue?
The current revenue for Recombinetics is .
-
How much funding has Recombinetics raised over time?
Recombinetics has raised $71.7M.
-
Who are Recombinetics’s investors?
National Cancer Institute, National Institute of Dental and Craniofacial Research, Edge (Onalaska), National institutes of Neurological Disorders and Stroke, and The National Institute on Aging (NIA) are 5 of 11 investors who have invested in Recombinetics.
-
Who are Recombinetics’s competitors?
ProFactor Pharma, Intellia Therapeutics, Voyager Therapeutics, Qrons, and CRISPR Therapeutics are some of the 35 competitors of Recombinetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
